TRAVEL EXPERT (01235) enters into a call option deed
TRAVEL EXPERT (01235) announced that on October 28, 2026, Dingkun Enterprise Limited (Dingkun Enterprise), an indirectly wholly-owned subsidiary of the Company, as grantee, entered into a call option deed with an independent third party (the grantor). Pursuant to which, the grantor agreed to grant Dingkun Enterprise a call option to acquire all shares held by the grantor in the target company at an option consideration of HK$1.4605 million. The option price was determined by reference to the net asset value of the target company plus a slight premium. Dingkun Enterprise shall pay HK$1 million as an initial refundable deposit on the date of the deed, with the balance payable upon completion.
TRAVEL EXPERT (01235) announced that on October 28, 2026, Dingkun Enterprise Limited (Dingkun Enterprise), an indirectly wholly-owned subsidiary of the Company, as grantee, entered into a call option deed with an independent third party (the grantor). Pursuant to which, the grantor agreed to grant Dingkun Enterprise a call option to acquire all shares held by the grantor in the target company at an option consideration of HK$1.4605 million. The option price was determined by reference to the net asset value of the target company plus a slight premium. Dingkun Enterprise is required to pay HK$1 million as an initial refundable deposit on the date of the deed, with the balance payable upon completion.
It is understood that the target company is an investment holding company, and the entity it holds is principally engaged in the sale of travel-related products and services. As at the date of the deed, the grantor is the controlling shareholder of the target company.
Related Articles

JUNSHI BIO (01877): Toripalimab Receives Conventional Approval from the National Medical Products Administration for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma That Has Failed Platinum-Containing Chemotherapy

US Stock Market Move | Memory concept stocks broadly rise; SK Hynix (SKHY.US) surges nearly 10% after earnings.

CLOUDR (09955): Subsidiary Anhui Shengda plans to buy back approximately 4.26% equity sold for RMB21.8408 million
JUNSHI BIO (01877): Toripalimab Receives Conventional Approval from the National Medical Products Administration for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma That Has Failed Platinum-Containing Chemotherapy

US Stock Market Move | Memory concept stocks broadly rise; SK Hynix (SKHY.US) surges nearly 10% after earnings.

CLOUDR (09955): Subsidiary Anhui Shengda plans to buy back approximately 4.26% equity sold for RMB21.8408 million






